Discrete conformations of epitope II on the hepatitis C virus E2 protein for antibody-mediated neutralization and nonneutralization

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 29, 2014, Pages 10690-10695

  Deng, Lu ^a   Ma, Li ^a   Virata Theimer, Maria Luisa ^a   Zhong, Lilin ^a   Yan, Hailing ^a   Zhao, Zhong ^a   Struble, Evi ^a   Feinstone, Stephen ^b   Alter, Harvey ^c   Zhang, Pei ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Immunoglobulins; Prophylaxis; Vaccine

Indexed keywords

EPITOPE; EPITOPE II; GLYCOPROTEIN E2; IMMUNOGLOBULIN F(AB) FRAGMENT; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; HEPATITIS C VIRUS; HYDROGEN BOND; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; VIRUS ENTRY; X RAY CRYSTALLOGRAPHY; X RAY DIFFRACTION;

IMMUNOGLOBULINS; PROPHYLAXIS; VACCINE;

AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; CONSERVED SEQUENCE; CRYSTALLOGRAPHY, X-RAY; EPITOPES; HEPACIVIRUS; HEPATITIS C ANTIBODIES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PROTEIN CONFORMATION; VIRAL ENVELOPE PROTEINS;

EID: 84904609849     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1411317111     Document Type: Article

References (32)

1. Centers for Disease Control and Prevention (2012) CDC Health Information for International Travel (Oxford Univ Press, New York).
2. Alter HJ, Seeff LB (2000) Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome. Semin Liver Dis 20(1):17-35. (Pubitemid 30421406)
3. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases (2009) Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 49(4):1335-1374.
4. Pileri P, et al. (1998) Binding of hepatitis C virus to CD81. Science 282(5390):938-941. (Pubitemid 28507525)
5. Flint M, et al. (1999) Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 73(8):6235-6244. (Pubitemid 29327798)
6. Drummer HE, Boo I, Maerz AL, Poumbourios P (2006) A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry. J Virol 80(16):7844-7853. (Pubitemid 44182285)
7. Ray R, et al. (2010) Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins. J Infect Dis 202(6):862-866.
8. Law M, et al. (2008) Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14(1):25-27.
9. Dorner M, et al. (2013) Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 501(7466):237-241.
10. Zhao Z, et al. (2014) A neutralization epitope in the hepatitis C virus E2 glycoprotein interacts with host entry factor CD81. PLoS ONE 9(1):e84346.
11. Kong L, et al. (2013) Hepatitis C virus E2 envelope glycoprotein core structure. Science 342(6162):1090-1094.
12. Zhang P, et al. (2007) Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci USA 104(20):8449-8454. (Pubitemid 47175508)
13. Duan H, et al. (2012) Amino acid residue-specific neutralization and nonneutralization of hepatitis C virus by monoclonal antibodies to the E2 protein. J Virol 86(23):12686-12694.
14. Zhang P, et al. (2009) Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci USA 106(18):7537-7541.
15. Deng L, et al. (2013) Structural evidence for a bifurcated mode of action in the antibody-mediated neutralization of hepatitis C virus. Proc Natl Acad Sci USA 110(18):7418-7422.
16. Collaborative Computational Project, Number 4 (1994) The CCP4 suite: Programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50(Pt 5):760-763.
17. Lawrence MC, Colman PM (1993) Shape complementarity at protein/protein interfaces. J Mol Biol 234(4):946-950. (Pubitemid 24027225)
18. Khan AG, et al. (2014) Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 509(7500):381-384.
19. Krey T, et al. (2013) Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape. PLoS Pathog 9(5):e1003364.
20. Logvinoff C, et al. (2004) Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci USA 101(27):10149-10154. (Pubitemid 38891210)
21. Burioni R, et al. (2001) Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs. Virology 288(1):29-35. (Pubitemid 32846471)
22. Creighton TE (1994) Proteins: Structures and Molecular Properties. 2nd ed (WH Freeman, New York).
23. Yan BX, Sun YQ (1997) Glycine residues provide flexibility for enzyme active sites. J Biol Chem 272(6):3190-3194. (Pubitemid 27066807)
24. Stanfield R, et al. (1999) Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing fabs. Structure 7(2):131-142. (Pubitemid 29159699)
25. Sharon M, et al. (2003) Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Structure 11(2):225-236. (Pubitemid 36183646)
26. Rosen O, et al. (2005) Induced fit in HIV-neutralizing antibody complexes: Evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization. Biochemistry 44(19):7250-7258. (Pubitemid 40656668)
27. Scheib H, Sperisen P, Hartley O (2006) HIV-1 coreceptor selectivity: Structural analogy between HIV-1 V3 regions and chemokine beta-hairpins is not the explanation. Structure 14(4):645-647, discussion 649-651.
28. Zolla-Pazner S, Cardozo T (2010) Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol 10(7):527-535.
29. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276(Pt A):307-326.
30. Storoni LC, McCoy AJ, Read RJ (2004) Likelihood-enhanced fast rotation functions. Acta Crystallogr D Biol Crystallogr 60(Pt 3):432-438. (Pubitemid 41087570)
31. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53(Pt 3):240-255. (Pubitemid 27235885)
32. Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66(Pt 4):486-501.